Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jul;52(7):e13768.
doi: 10.1111/eci.13768. Epub 2022 Mar 26.

The role of microbiota in nonalcoholic fatty liver disease

Agostino Di Ciaula  1 , Leonilde Bonfrate  1 , Piero Portincasa  1
Affiliations
Review

The role of microbiota in nonalcoholic fatty liver disease

Agostino Di Ciaula et al. Eur J Clin Invest. 2022 Jul.

Abstract

Nonalcoholic fatty liver disease (NAFLD) is the most frequent liver disease worldwide. Gut microbiota can play a role in the pathogenesis of NAFLD since dysbiosis is associated with reduced bacterial diversity, altered Firmicutes/Bacteroidetes ratio, a relative abundance of alcohol-producing bacteria, or other specific genera. Changes can promote disrupted intestinal barrier and hyperpermeability, filtration of bacterial products, activation of the immune system, and pro-inflammatory changes in the intestine, in the liver, and at a systemic level. Microbiota-derived molecules can contribute to the steatogenic effects. The link between gut dysbiosis and NAFLD, however, is confused by several factors which include age, BMI, comorbidities, dietary components, and lifestyle. The role of toxic chemicals in food and water requires further studies in both gut dysbiosis and NAFLD. We can anticipate that gut microbiota manipulation will represent a potential therapeutic tool to delay or reverse the progression of NAFLD, paving the way to primary prevention measures.

Keywords: Metabolome; fatty liver; gut-liver axis; intestine; liver steatosis; metabolic syndrome; microbiota.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

REFERENCES

    1. Di Ciaula A, Baj J, Garruti G, et al. Liver steatosis, gut-liver axis, microbiome and environmental factors. A never-ending bidirectional cross-talk. J Clin Med. 2020;9(8):2648.
    1. Di Palo DM, Garruti G, Di Ciaula A, et al. Increased colonic permeability and lifestyles as contributing factors to obesity and liver steatosis. Nutrients. 2020;12:E564.
    1. Di Ciaula A, Carbone F, Shanmugham H, et al. Adiponectin involved in portal flow hepatic extraction of 13C-metacethin in obesity and non-alcoholic fatty liver. Eur J Intern Med. 2021.
    1. Di Ciaula A, Passarella S, Shanmugam H, et al. Nonalcoholic fatty liver disease (NAFLD). mitochondria as players and targets of therapies? Int J Mol Sci 2021;22:5375.
    1. Portincasa P, Di Ciaula A, Garruti G, Vacca M, De Angelis M, Wang DQ. Bile acids and GPBAR-1: dynamic interaction involving genes, environment and gut microbiome. Nutrients. 2020;12(12):3709

LinkOut - more resources